Mascarenhas, J. O., Rampal, R., El Chaer, F., Gupta, V., Shimoda, K., Kiladjian, J.-J., … Harrison, C. (2024). A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis. Blood, 144(Supplement 1), 6629–6629. https://doi.org/10.1182/blood-2024-200268

Mascarenhas, John O., Raajit Rampal, Firas El Chaer, Vikas Gupta, Kazuya Shimoda, Jean-Jacques Kiladjian, Francesco Passamonti, et al. “A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis.” Blood 144, no. Supplement 1 (November 5, 2024): 6629–6629. https://doi.org/10.1182/blood-2024-200268.

Mascarenhas JO, Rampal R, El Chaer F, Gupta V, Shimoda K, Kiladjian J-J, et al. A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis. Blood. 2024 Nov 5;144(Supplement 1):6629–6629.

Mascarenhas, John O., et al. “A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, Nov. 2024, pp. 6629–6629. Crossref, doi:10.1182/blood-2024-200268.

Mascarenhas JO, Rampal R, El Chaer F, Gupta V, Shimoda K, Kiladjian J-J, Passamonti F, Bose P, Scandura JM, Mesa R, Rein LAM, Yuda J, Ross DM, Devos T, Talpaz M, Hoffman R, Kabir S, Li Z, Foulks JM, Ansaldo K, Seki M, Peddagali V, Shah J, Harrison C. A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis. Blood. American Society of Hematology; 2024 Nov 5;144(Supplement 1):6629–6629.